Correlation of Tissue and Plasma RANTES Levels with Disease Course in Patients with Breast or Cervical Cancer

Yukie Niwa, Hirohiko Akamatsu, Hayato Niwa, Hajime Sumi, Yukio Ozaki, and Akio Abe

Niwa Institute for Immunology, Tosashimizu 787-0303 [Y. N., H. A.]; Department of Dermatology, Kansai Medical University, Moriguchi 570-8507 [H. A.]; Gynecological Department, Hyogo Prefectural Amagasaki Hospital, Amagasaki 660-0828 [H. N.]; Department of Clinical and Laboratory Medicine, Yamanashi Medical University, Niwa Institute for Immunology, Tosashimizu 787-0303 [Y. N., H. S.]; Yukie Niwa, 1 Hirohiko Akamatsu, Hayato Niwa, Yamanashi Medical University, Yamanashi 409-3898 [Y. O.]; and Research and Development, Sumitomo Metal Bio-Science, Inc., Sagamihara 229-0004 [A. A.], Japan

ABSTRACT

The β-chemokine RANTES was measured in plasma in 43 patients with breast cancer and in 23 patients with cervical cancer, and the RANTES content in primary tumors, tumor metastatic to lymph nodes, and clinically normal skin or pelvic mucosa was measured. In addition, plasma levels were determined in all of the patients for the platelet-derived chemokine β-thromboglobulin (β-TG) and for IFN-γ, interleukin (IL)-2, IL-4, IL-5, and IL-10, along with serum IgE levels and blood eosinophils. Plasma RANTES levels were found to be higher in order of stages IV, III, II, and I of each cancer except for stage I. A marked increase in plasma RANTES level (>10,000 pg/ml) was found in 27% of patients with progressive malignancy but in none of those in clinical remission. The platelet RANTES content was correspondingly decreased in those patients with increased plasma RANTES levels. β-TG showed a pattern similar to RANTES both in plasma and platelets, but with much less dramatic differences between patients with different stages of disease. Other allergic parameters, IgE, eosinophils and plasma IFN-γ, IL-2, IL-5, and IL-10, were not elevated in the cancer patients. The RANTES content was markedly elevated in the primary tumor and metastatic lesions (lymph node or skin) from all of the patients with breast or cervical cancer, irrespective of the plasma RANTES level. In addition, in patients with progressive breast or cervical cancer, but not in patients thought to be cured of these tumors, the RANTES content was markedly increased in clinically normal tissue taken from near the operative site several months postoperatively, as well as in intact skin or mucosa taken perioperatively near the excised tumor. This study suggests an as-yet-undefined but important role played by RANTES in carcinogenesis, as well as the possibility that a RANTES assay in tissue surrounding a tumor or postoperative tumor site may help predict prognosis in these patients.

INTRODUCTION

RANTES (regulated upon activation, normal T-cell-expressed and secreted), which is one of the β (C-C) chemokines (1–12) that are chemoattractant for a variety of cells, particularly mononuclear cells, basophils, and eosinophils, is thought to be released by activated T lymphocytes and monocytes/macrophages (12), epithelial cells (7), bronchial epithelium (8, 9), and dermal fibroblast (10) and renal tubular epithelium (11). RANTES is thought to play an important role in a variety of disease states, including allergic inflammatory processes such as asthma, allergic rhinitis, and atopic dermatitis (13–17). We have found that plasma RANTES levels are significantly increased in the patients with severe, treatment-resistant atopic dermatitis (18).

Recently, it has been reported that platelets are also an important source of RANTES, and that platelet-released RANTES may play a role in allergic reaction (1–6). In this study, the levels of RANTES and another platelet-produced chemokine, β-TG, and the levels of IFN-γ, IL-2, IL-4, IL-5, and IL-10 which are known to be produced by Th1 and Th2 T lymphocytes and increased in RANTES-relating allergic inflammatory process (5, 6, 19–27) were assessed in the patients with various malignancies. The levels of (IL-4-stimulated) IgE and blood (IL-5-stimulated) eosinophils, both of which increase with the elevation in RANTES in allergic reactions, were also assessed. RANTES and β-TG content of platelets was also assayed, and RANTES was also measured in primary and metastatic tumors, and in clinically uninvolved tissue taken peri- or postoperatively. The results indicate a strong correlation between elevated tissue RANTES levels and progressive malignancy.

PATIENTS AND METHODS

Forty-three patients with breast cancer and 23 cases of cervical cancer (all females, ages 23–56 years) were studied. The patients were classified into four stages according to 1997 TNM classification. The diagnosis of each cancer was made by tumor biopsy, imaging studies (computed tomography scan, magnetic resonance imaging) and corresponding tumor markers. “Uncontrolled or progressive stage” was diagnosed by the appearance of relapse, metastasis, or other worsening clinical findings, including an increase in tumor size on imaging studies and rise in plasma and tumor markers. Patients with inflamma-

Received 6/19/00; revised 11/17/00; accepted 11/20/00.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Niwa Institute for Immunology, 4-4 Asahimachi, Tosashimizu 787-0303, Japan. Phone: 81-8808-2-2511; Fax: 81-8808-2-4925; E-mail: yniwa@lime.ocn.ne.jp.

2 The abbreviations used are: β-TG, β-thromboglobulin; IL, interleukin; CIS, carcinoma in situ.
Table 1  The levels of RANTES and β-TG in plasma and platelets in patients with breast and cervical cancers according to clinical stage and in progression or in remission

<table>
<thead>
<tr>
<th>Subjects</th>
<th>Stage</th>
<th>No. of cases with RANTES levels</th>
<th>RANTES pg/ml</th>
<th>No. of cases with RANTES levels</th>
<th>RANTES pg/ml</th>
<th>No. of cases with RANTES levels</th>
<th>RANTES pg/ml</th>
<th>No. of cases with RANTES levels</th>
<th>RANTES pg/ml</th>
<th>No. of cases with RANTES levels</th>
<th>RANTES pg/ml</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer patients</td>
<td>I (5)</td>
<td>0 (0)</td>
<td>1,706 ± 183</td>
<td>0 (0)</td>
<td>1,196 ± 104</td>
<td>136 ± 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>II (11)</td>
<td>1 (1)</td>
<td>1,498 ± 124</td>
<td>1 (1)</td>
<td>1,251 ± 106</td>
<td>124 ± 11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>III (12)</td>
<td>2 (2)</td>
<td>1,409 ± 128</td>
<td>2 (2)</td>
<td>1,395 ± 120</td>
<td>108 ± 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV (15)</td>
<td>4 (4)</td>
<td>1,112 ± 126</td>
<td>4 (4)</td>
<td>1,496 ± 138</td>
<td>98 ± 11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical cancer patients</td>
<td>I (3)</td>
<td>0 (0)</td>
<td>1,698 ± 176</td>
<td>0 (0)</td>
<td>1,203 ± 116</td>
<td>137 ± 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>II (4)</td>
<td>2 (2)</td>
<td>1,550 ± 162</td>
<td>2 (2)</td>
<td>1,229 ± 121</td>
<td>126 ± 13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>III (6)</td>
<td>2 (2)</td>
<td>1,369 ± 115</td>
<td>2 (2)</td>
<td>1,346 ± 113</td>
<td>114 ± 13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>IV (10)</td>
<td>3 (3)</td>
<td>1,204 ± 141</td>
<td>3 (3)</td>
<td>1,428 ± 145</td>
<td>108 ± 11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with breast and cervical cancers</td>
<td>Progressive (45)</td>
<td>12 (12)</td>
<td>1,125 ± 138</td>
<td>12 (12)</td>
<td>1,462 ± 130</td>
<td>103 ± 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>In remission (21)</td>
<td>2 (2)</td>
<td>1,684 ± 181</td>
<td>2 (2)</td>
<td>1,114 ± 112</td>
<td>128 ± 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy volunteers (12)</td>
<td></td>
<td>2 (2)</td>
<td>1,866 ± 175</td>
<td>2 (2)</td>
<td>909 ± 82</td>
<td>140 ± 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

a Parentheses denotes the number of the cases tested.
b 0.01 < P < 0.05 versus healthy volunteers.
c  P < 0.01.
shown in Table 1, plasma RANTES levels correlated directly with clinical stage for both breast and cervical cancer.

This correlation is also seen when patients were classified either as having progressive disease or as being in remission. As indicated in Table 1, mean plasma RANTES levels were significantly elevated in the patients with progressive and uncontrolled malignancy, compared with those in remission, and both groups showed elevated levels compared with healthy individuals. Moreover, in contrast to patients in remission and healthy volunteers, the distribution of RANTES levels in cancer patients with progressive disease showed a bimodal distribution. As shown in Fig. 1, the mean RANTES level in the first group was 11,435 pg/ml and that of the second group was 3,864 pg/ml, which is similar to that of the patients in remission. Of the patients with progressive disease, 27% of the patients in progression had a plasma RANTES level of >10,000 pg/ml, compared with none in either the group of cancer patients (the second group of progressive patients and the controlled group) or the healthy control group.

Because RANTES is produced from platelets, we measured levels of another platelet-secreted cytokine, β-TG, as a specificity control. The plasma levels of β-TG showed a modest correlation with cancer stage, but were much less dramatically elevated than those of RANTES (Table 1). The platelet content of both RANTES and β-TG were decreased in the patients with stage III or IV cancer, compared with healthy volunteers (0.01 < P < 0.05; Table 1), but, again, the decrease in RANTES content was more pronounced.

Interestingly, the other parameters that were measured, including IgE, eosinophils, IFN-γ, and IL-2, -4, -5, -8, and -10, were not significantly elevated in the cancer patients in whom plasma RANTES levels were found to be increased, nor in the cancer patients as a whole, compared with the healthy controls (data not shown).

**RANTES Content in Tissues.** The mean RANTES content of primary or metastatic tumor from patients with breast or cervical cancer was 50-fold greater than that of normal skin of healthy volunteers (breast cancer, P < 0.0001; invasive cervical cancer, P < 0.00001) and at least 5-fold greater than that of postoperative skin (as defined in “Patients and Methods”) or normal skin or mucosa taken at surgery near the site of the original tumor (breast cancer, P < 0.001; invasive cervical cancer, P < 0.01; Table 2). Both invasive cervical cancer and CIS of the cervix showed markedly elevated RANTES levels, although somewhat lower than in primary breast tumors. An increased RANTES content was found in all of the breast and cervical tumors examined, although only one-fourth of these patients showed elevated plasma RANTES levels. The RANTES content in the clinically normal skin or mucosa, taken perioperatively near original tumor or metastatic lesions from the patients with progression, relapse, and/or metastasis, was also markedly (7–10 times) increased compared with those from the biopsy specimens from patients in remission and from healthy controls (breast cancer, P < 0.001; invasive cervical cancer, P < 0.0001; Table 2), whereas there was no significant difference in the RANTES content of specimens from the latter two groups.

**DISCUSSION**

The β-chemokine RANTES is now known to be chemoattractant for monocytes and eosinophils and to play a major role in allergic inflammatory processes (13–17, 19), and investigation on a receptor for IgE on platelet and the correlation of allergic reaction-inducing IgE (5, 6, 13, 14, 32) and eosinophils (2, 3, 33) or basophils (34) to RANTES has been reported. RANTES expression in atopic dermatitis skin, and allergen-induced transcription of mRNA for RANTES and subfamily of RANTES, MCP3, and an increase in plasma RANTES levels have been reported. More recently, we have again observed a marked increase in plasma RANTES levels accompanied by a marked decrease in IL-10 levels in one-third of patients with severe, treatment-resistant atopic dermatitis, as well as a marked increase in the RANTES content of skin lesions and in improved or normal skin from these patients (18). In this study, we have observed that RANTES levels were markedly increased in the plasma of one-fourth of patients with advanced breast or cervical cancer. Moreover, the RANTES content in all of the specimens of tumor, metastases-containing lymph nodes, or tumor-involved skin or mucosa was markedly increased. We also have observed similar patterns of plasma RANTES levels in patients with many other malignancies.3 Markedly elevated levels of plasma RANTES (>10,000 pg/ml) were found only in 27% of patients with progressive cancer, whereas those in remission had normal levels. However, because only 27% of the patients with progressive cancer had elevated levels, the role of RANTES in cancer progression, if any, remains to be determined. It is, of course, possible that RANTES plays a key role in this process in some patients but not in others.

3 Unpublished data.
RANTES Levels in Cancer Patients

Although RANTES is known to be released by a variety of cells, including activated T lymphocytes, monocytes, and fibroblasts, there is a suggestion that the elevated plasma RANTES levels seen in some of the patients in this study were derived from platelets. RANTES is known to be produced by platelets, with strong effects on allergic processes (1–6). Moreover, the platelet-secreted chemokine β-TG was also increased in the plasma of the patients with elevated plasma RANTES levels, and these same patients had decreased RANTES and β-TG content in platelets. We have previously observed a similar pattern in patients with severe atopic dermatitis (18). From the above findings, it is not unlikely that elevated plasma RANTES in the patients with severe atopic dermatitis and malignancies derives from platelets.

The patients with elevated RANTES levels in plasma had normal blood levels of IgE, eosinophils, IFN-γ, and IL-2, -4, -5, and -10. The stimulus for RANTES secretion in association with normal blood levels of IgE, eosinophils, IFN-γ derives from platelets. We have previously observed a similar pattern in patients with elevated plasma RANTES levels seen in some of the patients in this study were derived from platelets. RANTES is known to be released by a variety of cells, including activated T lymphocytes, monocytes, and fibroblasts, there is a suggestion that the elevated plasma RANTES levels seen in some of the patients in this study were derived from platelets. RANTES is known to be produced by platelets, with strong effects on allergic processes (1–6). Moreover, the platelet-secreted chemokine β-TG was also increased in the plasma of the patients with elevated plasma RANTES levels, and these same patients had decreased RANTES and β-TG content in platelets. We have previously observed a similar pattern in patients with severe atopic dermatitis (18). From the above findings, it is not unlikely that elevated plasma RANTES in the patients with severe atopic dermatitis and malignancies derives from platelets.

The patients with elevated RANTES levels in plasma had normal blood levels of IgE, eosinophils, IFN-γ, and IL-2, -4, -5, and -10. The stimulus for RANTES secretion in association with normal blood levels of IgE, eosinophils, IFN-γ derives from platelets. We have previously observed a similar pattern in patients with severe atopic dermatitis (18). From the above findings, it is not unlikely that elevated plasma RANTES in the patients with severe atopic dermatitis and malignancies derives from platelets.

The patients with elevated RANTES levels in plasma had normal blood levels of IgE, eosinophils, IFN-γ, and IL-2, -4, -5, and -10. The stimulus for RANTES secretion in association with normal blood levels of IgE, eosinophils, IFN-γ derives from platelets. We have previously observed a similar pattern in patients with severe atopic dermatitis (18). From the above findings, it is not unlikely that elevated plasma RANTES in the patients with severe atopic dermatitis and malignancies derives from platelets.

Regarding the literature on the association of chemokines with malignancy, Iantorno et al. (35) reported that monocytes from the patients with bladder carcinoma undergoing BCG immunotherapy were stimulated in the presence of the β-chemokine MCP-1. Youngs et al. (36) reported that β-chemokines induced migrational responses in human breast carcinoma cells. Expression of RANTES and of MIP-1α and β in ovarian cancer (37) and the loss of tumorigenicity in vivo by RANTES secretion by gene-modified tumor cells (38) have also been demonstrated. However, there are no previous reports of RANTES levels in plasma, tumor, or perioperative tissue in cancer patients, nor has the correlation between RANTES levels and cancer disease course been previously described.

It is noteworthy that RANTES content was markedly increased in both perioperative and postoperative skin from patients with progressive breast or cervical cancer, whereas this was not the case in any of the patients thought to be cured or in remission. The RANTES content of peri- or postoperative biopsy sites would thus appear to have a prognostic value with regard to subsequent tumor relapse. The correlation of elevated RANTES content in diseased tissue seems to be much stronger than the correlation of elevated plasma RANTES, which suggests some fundamental role for RANTES in the lesions.

### REFERENCES


Correlation of Tissue and Plasma RANTES Levels with Disease Course in Patients with Breast or Cervical Cancer

Yukie Niwa, Hirohiko Akamatsu, Hayato Niwa, et al.


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/7/2/285

Cited articles
This article cites 32 articles, 11 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/7/2/285.full#ref-list-1

Citing articles
This article has been cited by 25 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/7/2/285.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.